These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1801543)

  • 1. Nigral degeneration in Parkinson's disease in relation to clinical features.
    Rinne JO
    Acta Neurol Scand Suppl; 1991; 136():87-90. PubMed ID: 1801543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nigral degeneration in Parkinson's disease.
    Rinne JO
    Mov Disord; 1993; 8 Suppl 1():S31-5. PubMed ID: 8302305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease.
    Rinne JO; Röyttä M; Paljärvi L; Rummukainen J; Rinne UK
    Neurology; 1991 Jun; 41(6):859-61. PubMed ID: 1904564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia.
    Rinne JO; Rummukainen J; Paljärvi L; Säkö E; Mölsä P; Rinne UK
    Prog Clin Biol Res; 1989; 317():325-32. PubMed ID: 2602422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
    Youdim MB; Riederer P
    Mov Disord; 1993; 8 Suppl 1():S8-13. PubMed ID: 8302308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract]   [Full Text] [Related]  

  • 8. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
    Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
    J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
    Weise D; Lorenz R; Schliesser M; Schirbel A; Reiners K; Classen J
    Mov Disord; 2009 Aug; 24(11):1669-75. PubMed ID: 19514075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
    Olanow CW
    Mov Disord; 1993; 8 Suppl 1():S1-7. PubMed ID: 8302302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nigrostriatal system in Parkinson's disease.
    Graybiel AM; Hirsch EC; Agid Y
    Adv Neurol; 1990; 53():17-29. PubMed ID: 1978514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
    Jellinger KA
    J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
    Metman LV; Konitsiotis S; Chase TN
    Mov Disord; 2000 Jan; 15(1):3-8. PubMed ID: 10634235
    [No Abstract]   [Full Text] [Related]  

  • 15. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain.
    Cooper JM; Daniel SE; Marsden CD; Schapira AH
    Mov Disord; 1995 May; 10(3):295-7. PubMed ID: 7651446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O
    Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Pure" striatonigral degeneration and Parkinson's disease: a comparative clinical study.
    Gouider-Khouja N; Vidailhet M; Bonnet AM; Pichon J; Agid Y
    Mov Disord; 1995 May; 10(3):288-94. PubMed ID: 7651445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of dopaminergic agents in Parkinson's disease.
    Koller WC; Rueda MG
    Neurology; 1998 Jun; 50(6 Suppl 6):S11-4; discussion S44-8. PubMed ID: 9633680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa.
    Zigmond MJ; Abercrombie ED; Stricker EM
    J Neural Transm Suppl; 1990; 29():217-32. PubMed ID: 2193107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.